Search

Your search keyword '"MASK-AIR"' showing total 18 results
Start Over Descriptor "MASK-AIR" Search Limiters Available in Library Collection
18 results on '"MASK-AIR"'

1. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach.

Author

Bousquet, Jean, Anto, Josep M., Sousa‐Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S., Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C., Bosnic‐Anticevich, Sinthia, Brussino, Luisa, and Canonica, G. Walter

Subjects
*RHINITIS, *MEDICAL laws, *ASTHMA, *COMORBIDITY, *ALLERGIC rhinitis
Abstract

MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co‐operation and Development). MASK‐air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK‐air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical practice and trials. The implications of the novel MASK‐air® results should lead to change management in rhinitis and asthma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

2. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach

Author

Jean Bousquet, Josep M. Anto, Bernardo Sousa‐Pinto, Wienczyslawa Czarlewski, Anna Bedbrook, Tari Haahtela, Ludger Klimek, Oliver Pfaar, Piotr Kuna, Maciej Kupczyk, Frederico S. Regateiro, Boleslaw Samolinski, Arunas Valiulis, Arzu Yorgancioglu, Sylvie Arnavielhe, Xavier Basagaña, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Claudia Chaves‐Loureiro, Elisio Costa, Alvaro A. Cruz, Bilun Gemicioglu, Wytske J. Fokkens, Juan Carlos Ivancevich, Helga Kraxner, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Daniel Laune, Renaud Louis, Michael Makris, Marcus Maurer, Erik Melén, Yann Micheli, Mario Morais‐Almeida, Joaquim Mullol, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Philip W. Rouadi, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Mikhail Sofiev, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Erkka Valovirta, Maria Teresa Ventura, Rafael José Vieira, Mihaela Zidarn, Rita Amaral, Ignacio J. Ansotegui, Annabelle Bédard, Samuel Benveniste, Michael Bewick, Carsten Bindslev‐Jensen, Hubert Blain, Matteo Bonini, Rodolphe Bourret, Fulvio Braido, Pedro Carreiro‐Martins, Denis Charpin, Ivan Cherrez‐Ojeda, Tomas Chivato, Derek K. Chu, Cemal Cingi, Stefano DelGiacco, Frédéric deBlay, Philippe Devillier, Govert DeVries, Maria Doulaptsi, Virginie Doyen, Gérard Dray, Jean‐François Fontaine, R. Maximiliano Gomez, Jan Hagemann, Enrico Heffler, Maja Hofmann, Ewa Jassem, Marek Jutel, Thomas Keil, Vicky Kritikos, Inger Kull, Marek Kulus, Olga Lourenço, Eve Mathieu‐Dupas, Enrica Menditto, Ralph Mösges, Ruth Murray, Rachel Nadif, Hugo Neffen, Stefania Nicola, Robyn O’Hehir, Heidi Olze, Yuliia Palamarchuk, Jean‐Louis Pépin, Benoit Pétré, Robert Picard, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Filip Raciborski, Sietze Reitsma, Nicolas Roche, Monica Rodriguez‐Gonzalez, Jan Romantowski, Ana Sá‐Sousa, Faradiba S. Serpa, Marine Savouré, Mohamed H. Shamji, Milan Sova, Annette Sperl, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Olivier Vandenplas, Michiel VanEerd, Tuula Vasankari, Frédéric Viart, Susan Waserman, Joao A. Fonseca, and Torsten Zuberbier

Subjects
asthma, digital, MASK‐air, mHealth, rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co‐operation and Development). MASK‐air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK‐air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical practice and trials. The implications of the novel MASK‐air® results should lead to change management in rhinitis and asthma.

Published
2023
Full Text
View/download PDF

3. Mobile health app for monitoring allergic rhinitis and asthma in real life in Lithuanian MASK‐air users.

Author

Kvedarienė, Violeta, Biliute, Gabija, Didziokaitė, Gabija, Kavaliukaite, Loreta, Savonyte, Agne, Rudzikaite‐Fergize, Gabija, Puronaite, Roma, Norkuniene, Jolita, Emuzyte, Regina, Dubakiene, Ruta, Valiulis, Arunas, Sousa‐Pinto, Bernardo, Bedbrook, Anna, and Bousquet, Jean

Subjects
*MOBILE apps, *ALLERGIC rhinitis, *MOBILE health, *ASTHMA, *LITHUANIANS, *SATISFACTION
Abstract

Background: MASK‐air® is an app whose aim is to reduce the global burden of allergic rhinitis (AR) and asthma. A transfer of innovative practices was performed to disseminate and implement MASK‐air® in European regions. The aim of the study was to examine the implementation of the MASK‐air® app in Lithuanian adults in order to investigate (i) the rate of acceptance in this population, (ii) the duration of app use and (iii) the evaluation of the app after its use. Methods: In a longitudinal study, Lithuanian adults with AR and/or asthma were recruited by allergists. They were informed about how to use MASK‐air® and were followed closely. They were reviewed after one to 3 months to evaluate satisfaction and were asked to continue using the app. Results: Among the 149 patients recruited (37.2 ± 10.4 years), 52.4% had rhinitis alone, 42.9% had rhinitis, asthma and/or conjunctivitis multimorbidity, and 2.7% isolated asthma. According to the MASK‐air® baseline questionnaire, 88.3% of patients considered that their symptoms were troublesome. Data were available for 102 (68.4%) patients. The duration of app usage in patients ranged from 1 to 680 days (median, 25–75 percentile: 54, 23.2–151 days). Forty‐two (41.1% of patients who were reviewed) patients agreed to share their opinion on MASK‐air®. Most users of the app were satisfied, from 46.5% thinking their allergy was treated more successfully to 90.4% recommending this app to other allergy sufferers. Discussion: When recommended by physicians, MASK‐air® was used for a longer period of time. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

4. Mobile health app for monitoring allergic rhinitis and asthma in real life in Lithuanian MASK‐air users

Author

Violeta Kvedarienė, Gabija Biliute, Gabija Didziokaitė, Loreta Kavaliukaite, Agne Savonyte, Gabija Rudzikaite‐Fergize, Roma Puronaite, Jolita Norkuniene, Regina Emuzyte, Ruta Dubakiene, Arunas Valiulis, Bernardo Sousa‐Pinto, Anna Bedbrook, and Jean Bousquet

Subjects
asthma, Lithuania, MASK‐air, mHealth, rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background MASK‐air® is an app whose aim is to reduce the global burden of allergic rhinitis (AR) and asthma. A transfer of innovative practices was performed to disseminate and implement MASK‐air® in European regions. The aim of the study was to examine the implementation of the MASK‐air® app in Lithuanian adults in order to investigate (i) the rate of acceptance in this population, (ii) the duration of app use and (iii) the evaluation of the app after its use. Methods In a longitudinal study, Lithuanian adults with AR and/or asthma were recruited by allergists. They were informed about how to use MASK‐air® and were followed closely. They were reviewed after one to 3 months to evaluate satisfaction and were asked to continue using the app. Results Among the 149 patients recruited (37.2 ± 10.4 years), 52.4% had rhinitis alone, 42.9% had rhinitis, asthma and/or conjunctivitis multimorbidity, and 2.7% isolated asthma. According to the MASK‐air® baseline questionnaire, 88.3% of patients considered that their symptoms were troublesome. Data were available for 102 (68.4%) patients. The duration of app usage in patients ranged from 1 to 680 days (median, 25–75 percentile: 54, 23.2–151 days). Forty‐two (41.1% of patients who were reviewed) patients agreed to share their opinion on MASK‐air®. Most users of the app were satisfied, from 46.5% thinking their allergy was treated more successfully to 90.4% recommending this app to other allergy sufferers. Discussion When recommended by physicians, MASK‐air® was used for a longer period of time.

Published
2022
Full Text
View/download PDF

5. MASK (Mobile Airways Sentinel Network), a mobile App with ARIA’s comprehensive solution in Spanish-speaking countries

Author

Désirée Larenas-Linnemann, Joaquim Mullol, Juan Carlos Ivancevich, Josep M. Anto, Victoria Cardona, Toni Dedeu, Mónica Rodríguez-González, Yunuen Rocío Huerta-Villalobos, Hugo Neffen, José Miguel Fuentes-Pérez, Eréndira Rodríguez-Zagal, Antonio Valero, Mario Zernotti, Joan Bartra, Isam Alobid, José Antonio Castillo-Vizuete, Teresa Dordal, Rafael Hijano, César Picado, Joaquín Sastre, Ariel Eduardo Blua, Edgardo Jares, Alberto Jorge Lavrut, Jorge Máspero, Martín Bedolla-Barajas, María Teresa Burguete-Cabañas, María del Carmen Costa-Domínguez, Margarita Domínguez-Silva, Jesús Guillermo Espinoza-Contreras, José Luis Gálvez-Romero, Cecilia Yvonne García-Cobas, María de la Luz Hortensia García-Cruz, Luiana Hernández-Velázquez, Jorge A. Luna-Pech, Juan José Matta, María Dolores Mogica-Martínez, Daniela Rivero-Yeverino, Lucy Tania Ruiz, Blanca E. Del Río-Navarro, Javier Gómez-Vera, Alejandra Macías-Weinmann, Ruth Murray, Gabrielle Onorato, Daniel Laune, Anna Bedbrook, and Jean Bousquet

Subjects
app móvil, m-salud, asma, rinitis alérgica, conjuntivitis alérgica, mask-air, aria, Immunologic diseases. Allergy, RC581-607
Abstract

Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the “Allergy Diary” on the physician’s computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used.

Published
2019
Full Text
View/download PDF

6. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Zuberbier, Torsten, Savouré, Marine, Picard, Robert, Pitsios, Constantinos, Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Reitsma, Sietze, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romantowski, Jan, Sá-Sousa, Ana, Serpa, Faradiba S, Shamji, Mohamed H, Pépin, Jean-Louis, Sova, Milan, Sperl, Annette, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Vandenplas, Olivier, Van Eerd, Michiel, Vasankari, Tuula, Viart, Frédéric, Waserman, Susan, Fonseca, Joao A, Pétré, Benoit, Bousquet, Jean, Anto, Josep M, Sousa-Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S, Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Cecchi, Lorenzo, Chaves-Loureiro, Claudia, Costa, Elisio, Cruz, Alvaro A, Gemicioglu, Bilun, Fokkens, Wytske J, Ivancevich, Juan Carlos, Kraxner, Helga, Kvedariene, Violeta, Larenas-Linnemann, Désirée E, Laune, Daniel, Louis, Renaud, Makris, Michael, Maurer, Marcus, Melén, Erik, Micheli, Yann, Morais-Almeida, Mario, Mullol, Joaquim, Niedoszytko, Marek, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Rouadi, Philip W, Sastre, Joaquin, Scichilone, Nicola, Sheikh, Aziz, Sofiev, Mikhail, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, Ventura, Maria Teresa, Vieira, Rafael José, Zidarn, Mihaela, Amaral, Rita, Ansotegui, Ignacio J, Bédard, Annabelle, Benveniste, Samuel, Bewick, Michael, Bindslev-Jensen, Carsten, Blain, Hubert, Bonini, Matteo, Bourret, Rodolphe, Braido, Fulvio, Carreiro-Martins, Pedro, Charpin, Denis, Cherrez-Ojeda, Ivan, Chivato, Tomas, Chu, Derek K, Cingi, Cemal, Del Giacco, Stefano, de Blay, Frédéric, Devillier, Philippe, De Vries, Govert, Doulaptsi, Maria, Doyen, Virginie, Dray, Gérard, Fontaine, Jean-François, Gomez, R Maximiliano, Hagemann, Jan, Heffler, Enrico, Hofmann, Maja, Jassem, Ewa, Jutel, Marek, Keil, Thomas, Kritikos, Vicky, Kull, Inger, Kulus, Marek, Lourenço, Olga, Mathieu-Dupas, Eve, Menditto, Enrica, Mösges, Ralph, Murray, Ruth, Nadif, Rachel, Neffen, Hugo, Nicola, Stefania, O'Hehir, Robyn, Olze, Heidi, Palamarchuk, Yuliia, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Zuberbier, Torsten, Savouré, Marine, Picard, Robert, Pitsios, Constantinos, Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Reitsma, Sietze, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romantowski, Jan, Sá-Sousa, Ana, Serpa, Faradiba S, Shamji, Mohamed H, Pépin, Jean-Louis, Sova, Milan, Sperl, Annette, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Vandenplas, Olivier, Van Eerd, Michiel, Vasankari, Tuula, Viart, Frédéric, Waserman, Susan, Fonseca, Joao A, Pétré, Benoit, Bousquet, Jean, Anto, Josep M, Sousa-Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S, Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Cecchi, Lorenzo, Chaves-Loureiro, Claudia, Costa, Elisio, Cruz, Alvaro A, Gemicioglu, Bilun, Fokkens, Wytske J, Ivancevich, Juan Carlos, Kraxner, Helga, Kvedariene, Violeta, Larenas-Linnemann, Désirée E, Laune, Daniel, Louis, Renaud, Makris, Michael, Maurer, Marcus, Melén, Erik, Micheli, Yann, Morais-Almeida, Mario, Mullol, Joaquim, Niedoszytko, Marek, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Rouadi, Philip W, Sastre, Joaquin, Scichilone, Nicola, Sheikh, Aziz, Sofiev, Mikhail, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, Ventura, Maria Teresa, Vieira, Rafael José, Zidarn, Mihaela, Amaral, Rita, Ansotegui, Ignacio J, Bédard, Annabelle, Benveniste, Samuel, Bewick, Michael, Bindslev-Jensen, Carsten, Blain, Hubert, Bonini, Matteo, Bourret, Rodolphe, Braido, Fulvio, Carreiro-Martins, Pedro, Charpin, Denis, Cherrez-Ojeda, Ivan, Chivato, Tomas, Chu, Derek K, Cingi, Cemal, Del Giacco, Stefano, de Blay, Frédéric, Devillier, Philippe, De Vries, Govert, Doulaptsi, Maria, Doyen, Virginie, Dray, Gérard, Fontaine, Jean-François, Gomez, R Maximiliano, Hagemann, Jan, Heffler, Enrico, Hofmann, Maja, Jassem, Ewa, Jutel, Marek, Keil, Thomas, Kritikos, Vicky, Kull, Inger, Kulus, Marek, Lourenço, Olga, Mathieu-Dupas, Eve, Menditto, Enrica, Mösges, Ralph, Murray, Ruth, Nadif, Rachel, Neffen, Hugo, Nicola, Stefania, O'Hehir, Robyn, Olze, Heidi, and Palamarchuk, Yuliia

Abstract

MASK-air , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air results should lead to change management in rhinitis and asthma.

Published
2023

7. From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe).

Author

Sousa-Pinto B, Palamarchuk Y, Leemann L, Jankin S, Basagaña X, Ballester J, Bedbrook A, Czarlewski W, Almeida R, Haahtela T, Haveri H, Prass M, Henriques T, Vieira RJ, Klimek L, Ollert M, Shamji MH, Jutel M, Del Giacco S, Torres MJ, Zuberbier T, Fonseca JA, Sofiev M, Anto JM, and Bousquet J

Subjects
Humans, Allergens, Europe epidemiology, Catalysis, Rhinitis, Allergic, Asthma epidemiology, Asthma etiology
Abstract

Plant species vary under different climatic conditions and the distribution of pollen in the air. Trends in pollen distribution can be used to assess the impact of climate change on public health. In 2015, the Mobile Airways Sentinel networK for rhinitis and asthma (MASK-air®) was launched as a project of the European Innovation Partnership on Active and Healthy Ageing (EIP-on-AHA, DG Santé and DG CONNECT). This project aimed to develop a warning system to inform patients about the onset of the pollen season, namely, the System for Integrated modeLling of Atmospheric coMposition (SILAM). A global-to-meso-scale dispersion model was developed by the Finnish Meteorological Institute (FMI). It provides quantitative information on atmospheric pollution of anthropogenic and natural origins, particularly on allergenic pollens. Impact of Air Pollution on Asthma and Rhinitis (POLLAR, EIT Health) has combined MASK-air clinical data with SILAM forecasts. A new Horizon Europe grant (Climate Action to Advance HeaLthY Societies in Europe [CATALYSE]; grant agreement number 101057131), which came into force in September 2022, aims to improve our understanding of climate change and help us find ways to counteractit. One objective of this project is to develop early warning systems and predictive models to improve the effectiveness of strategies for adapting to climate change. One of the warning systems is focused on allergic rhinitis (CATALYSE Task 3.2), with a collaboration between the FMI (Finland), Porto University (Portugal), MASK-air SAS (France), ISGlobal (Spain), Hertie School (Germany), and the University of Zurich (Switzerland). It is to be implemented with the support of the European Academy of Allergy and Clinical Immunology. This paper reports the planning of CATALYSE Task 3.2.

Published
2024
Full Text
View/download PDF

8. MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana.

Author

Larenas-Linnemann, Désirée, Mullol, Joaquim, Ivancevich, Juan Carlos, Anto, Josep M., Cardona, Victoria, Dedeu, Toni, Rodríguez-González, Mónica, Huerta-Villalobos, Yunuen Rocío, Neffen, Hugo, Fuentes-Pérez, José Miguel, Rodríguez-Zagal, Eréndira, Valero, Antonio, Zernotti, Mario, Bartra, Joan, Alobid, Isam, Castillo-Vizuete, José Antonio, Dordal, Teresa, Hijano, Rafael, Picado, César, and Sastre, Joaquín

Abstract

Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the "Allergy Diary" on the physician's computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. The ARIA-MASK-air® approach

Author

Bousquet, Jean, Anto, Josep M., Sousa-Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S., Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Chaves-Loureiro, Claudia, Costa, Elisio, Cruz, Alvaro A., Gemicioglu, Bilun, Fokkens, Wytske J., Ivancevich, Juan Carlos, Kraxner, Helga, Kvedariene, Violeta, Larenas-Linnemann, Désirée E., Laune, Daniel, Louis, Renaud, Makris, Michael, Maurer, Marcus, Melén, Erik, Micheli, Yann, Morais-Almeida, Mario, Mullol, Joaquim, Niedoszytko, Marek, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Rouadi, Philip W., Sastre, Joaquin, Scichilone, Nicola, Sheikh, Aziz, Sofiev, Mikhail, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, Ventura, Maria Teresa, Vieira, Rafael José, Zidarn, Mihaela, Amaral, Rita, Ansotegui, Ignacio J., Bédard, Annabelle, Benveniste, Samuel, Bewick, Michael, Bindslev-Jensen, Carsten, Blain, Hubert, Bonini, Matteo, Bourret, Rodolphe, Braido, Fulvio, Carreiro-Martins, Pedro, Charpin, Denis, Cherrez-Ojeda, Ivan, Chivato, Tomas, Chu, Derek K., Cingi, Cemal, Del Giacco, Stefano, de Blay, Frédéric, Devillier, Philippe, De Vries, Govert, Doulaptsi, Maria, Doyen, Virginie, Dray, Gérard, Fontaine, Jean François, Gomez, R. Maximiliano, Hagemann, Jan, Heffler, Enrico, Hofmann, Maja, Jassem, Ewa, Jutel, Marek, Keil, Thomas, Kritikos, Vicky, Kull, Inger, Kulus, Marek, Lourenço, Olga, Mathieu-Dupas, Eve, Menditto, Enrica, Mösges, Ralph, Murray, Ruth, Nadif, Rachel, Neffen, Hugo, Nicola, Stefania, O’Hehir, Robyn, Olze, Heidi, Palamarchuk, Yuliia, Pépin, Jean Louis, Pétré, Benoit, Picard, Robert, Pitsios, Constantinos, Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Reitsma, Sietze, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romantowski, Jan, Sá-Sousa, Ana, Serpa, Faradiba S., Savouré, Marine, Shamji, Mohamed H., Sova, Milan, Sperl, Annette, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Vandenplas, Olivier, Van Eerd, Michiel, Vasankari, Tuula, Viart, Frédéric, Waserman, Susan, Fonseca, Joao A., Zuberbier, Torsten, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS

Subjects
Pulmonary and Respiratory Medicine, rhinitis, mHealth, digital, Immunology, Immunology and Allergy, asthma, MASK-air
Abstract

Funding Information: The authors thank Ms Véronique Pretschner for submitting the paper. MASK‐air has been supported by Charité Universitätsmedizin Berlin, EU grants (EU Structural and Development Funds Languedoc Roussillon and Region PACA; POLLAR: EIT Health; Twinning: EIP on AHA; Twinning DHE: H2020; Catalyse: Horizon Europe) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis, Stallergènes‐Greer and Uriach. None for the study. ® Publisher Copyright: © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma. publishersversion published

Published
2023

10. The ARIA approach of Value-Added Medicines:as-needed treatment in allergic rhinitis

Author

Bousquet, Jean, Toumi, Mondher, Sousa-Pinto, Bernardo, Anto, Josep M, Bedbrook, Anna, Czarlewski, Wienczyslawa, Valiulis, Arunas, Ansotegui, Ignacio J, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G Walter, Cecchi, Lorenzo, Cherrez-Ojeda, Ivan, Chivato, Tomas, Costa, Elísio M, Cruz, Alvaro A, Del Giacco, Stefano, Fonseca, Joao A, Gemicioglu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Jutel, Marek, Kaidashev, Igor, Klimek, Ludger, Kvedariene, Violeta, Kuna, Piotr, Larenas-Linnemann, Désirée E, Lipworth, Brian, Morais-Almeida, Mario, Mullol, Joaquim, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Rouadi, Philip W, Samolinski, Boleslaw, Sheikh, Aziz, Taborda-Barata, Luis, Ventura, Maria Teresa, Yorgancioglu, Arzu, Zidarn, Mihaela, and Zuberbier, Torsten

Subjects
Treatment, Value-added medicine, MASK-air, Repurposing, Allergic rhinitis
Abstract

Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.

Published
2022
Full Text
View/download PDF

11. MASK (Mobile Airways Sentinel Network). La solución integral de ARIA por app móvil para la multimorbilidad de rinitis alérgica y asma.

Author

Larenas-Linnemann, Désirée, Mullol, Joaquim, Ivancevich, Juan Carlos, Antó, Josep M., Cardona, Victoria, Dedeu, Toni, Rodríguez-González, Mónica, Huerta, Yunuen, Neffen, Hugo, Fuentes-Pérez, José Miguel, Rodríguez-Zagal, Eréndira, Valero, Antonio, Zernotti, Mario, Bartra, Joan, Alobid, Isam, Castillo-Vizuete, José Antonio, Dordal, Teresa, Hijano, Rafael, Picado, César, and Sastre, Joaquín

Abstract

The vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union against chronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient's cell phone, it first requests some information about the patient's profile, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work/school. After analyzing the data generated by filling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

12. Implementation of the MASK-Air® App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study

Author

Antonio Francesco Maria Giuliano, Anna Bedbrook, Vincenzo Patella, R. Buquicchio, Jean Bousquet, Giorgio Walter Canonica, Wienczyslawa Czarlewski, Maria Teresa Ventura, and Daniel Laune

Subjects
Male, medicine.medical_specialty, Low education, Immunology, Population, Pilot Projects, Elderly, Computer literacy, Humans, Immunology and Allergy, Medicine, Outpatient clinic, education, mHealth, Aged, Rhinitis, Asthma, Aged, 80 and over, education.field_of_study, business.industry, Age Factors, Mean age, General Medicine, Patient Acceptance of Health Care, MASK-Air, medicine.disease, Mobile Applications, Rhinitis, Allergic, Europe, Self Care, Physical therapy, Female, business, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, Follow-Up Studies
Abstract

Introduction: MASK-air® is an app whose aim is to reduce the global burden of allergic rhinitis and asthma. A transfer of innovative practices was performed to disseminate and implement MASK-air® in European regions. The aim of the study was to examine the implementation of the MASK-air® app in older adults of the Puglia TWINNING in order to investigate (i) the rate of acceptance in this population, (ii) the reasons for refusal and (iii) the evaluation of the app after its use. Methods: All consecutive geriatric patients aged between 65 and 90 years were included by the outpatient clinic of the Bari Geriatric Immunoallergology Unit. After a 1-h training session, older adults used the app for 6 months. A 6-item questionnaire was developed by our unit to evaluate the impact of the app on the management of the disease and its treatment. Results: Among the 174 recruited patients, 102 accepted to use the app (mean age, SD: 72.4 ± 4.6 years), 6 were lost to follow-up, and 63 had a low education level. The reasons given not to use the app included lack of interest (11%), lack of access to a smartphone or tablet (53%), low computer literacy (28%), and distrust (8%). At follow-up, the overall satisfaction was high (89%), the patient considered MASK-air® “advantageous” (95%), compliance to treatment was improved (81%), and the rate of loss to follow-up had decreased to 6%. Conclusion: Older adults with a low level of education can use the MASK-air® app after a short training session.

Published
2021
Full Text
View/download PDF

13. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Antó, Josep M, Pfaar, Oliver, Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J, Bergmann, Karl-Christian, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Tomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K, Cingi, Cemal, Costa, Elísio M, Cruz, Alvaro A, De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J, Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Reitsma, Sietze, Rouadi, Philip W, Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, Bousquet, Jean, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Antó, Josep M, Pfaar, Oliver, Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J, Bergmann, Karl-Christian, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Tomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K, Cingi, Cemal, Costa, Elísio M, Cruz, Alvaro A, De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J, Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Reitsma, Sietze, Rouadi, Philip W, Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, and Bousquet, Jean

Abstract

Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. We analysed 2015-2020 MASK-air European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ("VAS Global Symptoms") and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median "VAS Global Symptoms" was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p<0.001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. AR medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR), and that co-medication use is driven by symptom severity.

Published
2022

14. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data

Author

Bernardo Sousa‐Pinto, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Ludger Klimek, Wienczyslawa Czarlewski, Josep M. Antó, Oliver Pfaar, Anna Bedbrook, Violeta Kvedariene, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl‐Christian Bergmann, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Tomas Casale, Lorenzo Cecchi, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Giulia De Feo, Philippe Devillier, Wytske J. Fokkens, Mina Gaga, Bilun Gemicioğlu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Désirée E. Larenas‐Linnemann, Daniel Laune, Brian Lipworth, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Mikaëla Odemyr, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Olivier Vandenplas, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João A. Fonseca, Jean Bousquet, UAM. Departamento de Medicina, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Publica, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, and Department of Pathology

Subjects
Medicina, Immunology, Histamine Antagonists / therapeutic use, MASK-air, Co-medication, Allergic rhinitis, Visual analogue scales, Habits, allergic rhinitis, visual analogue scale, Visual analogue scale, 3121 General medicine, internal medicine and other clinical medicine, HDE ALER, Immunology and Allergy, Europe / epidemiology, Rhinitis, Allergic* / epidemiology, Rhinitis* / drug therapy
Abstract

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015–2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (‘VAS Global Symptoms’) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median ‘VAS Global Symptoms’ was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p, This study was funded by ARIA. MASK-air® has been supported by EU grants (EU Structural and Development grant, POLLAR: EIT Health and Structural and Development Funds) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open Access funding enabled and organized by Projekt DEAL

Published
2022

15. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air ® approach.

Author

Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, Klimek L, Pfaar O, Kuna P, Kupczyk M, Regateiro FS, Samolinski B, Valiulis A, Yorgancioglu A, Arnavielhe S, Basagaña X, Bergmann KC, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Cecchi L, Chaves-Loureiro C, Costa E, Cruz AA, Gemicioglu B, Fokkens WJ, Ivancevich JC, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Louis R, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Rouadi PW, Sastre J, Scichilone N, Sheikh A, Sofiev M, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Valovirta E, Ventura MT, Vieira RJ, Zidarn M, Amaral R, Ansotegui IJ, Bédard A, Benveniste S, Bewick M, Bindslev-Jensen C, Blain H, Bonini M, Bourret R, Braido F, Carreiro-Martins P, Charpin D, Cherrez-Ojeda I, Chivato T, Chu DK, Cingi C, Del Giacco S, de Blay F, Devillier P, De Vries G, Doulaptsi M, Doyen V, Dray G, Fontaine JF, Gomez RM, Hagemann J, Heffler E, Hofmann M, Jassem E, Jutel M, Keil T, Kritikos V, Kull I, Kulus M, Lourenço O, Mathieu-Dupas E, Menditto E, Mösges R, Murray R, Nadif R, Neffen H, Nicola S, O'Hehir R, Olze H, Palamarchuk Y, Pépin JL, Pétré B, Picard R, Pitsios C, Puggioni F, Quirce S, Raciborski F, Reitsma S, Roche N, Rodriguez-Gonzalez M, Romantowski J, Sá-Sousa A, Serpa FS, Savouré M, Shamji MH, Sova M, Sperl A, Stellato C, Todo-Bom A, Tomazic PV, Vandenplas O, Van Eerd M, Vasankari T, Viart F, Waserman S, Fonseca JA, and Zuberbier T

Abstract

MASK-air ® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air ® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air ® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air ® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air ® results should lead to change management in rhinitis and asthma., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)

Published
2023
Full Text
View/download PDF

16. MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana

Author

Javier Gómez-Vera, Jorge A. Luna-Pech, Erendira Rodriguez-Zagal, Joaquín Sastre, Joan Bartra, Juan Carlos Ivancevich, Teresa Dordal, Lucy Tania Ruiz, Antonio Valero, Mónica Rodríguez-González, Gabrielle L. Onorato, José Luis Gálvez-Romero, Martín Bedolla-Barajas, Désirée Larenas-Linnemann, Alberto Jorge Lavrut, Edgardo Jares, Luiana Hernández-Velázquez, María de la Luz Hortensia García-Cruz, María del Carmen Costa-Domínguez, Josep M. Antó, María Teresa Burguete-Cabañas, Jean Bousquet, Cecilia Yvonne García-Cobas, Jesús Guillermo Espinoza-Contreras, Mario E. Zernotti, José Antonio Castillo-Vizuete, Jorge Maspero, Hugo Neffen, Rafael Hijano, César Picado, Margarita Domínguez-Silva, Yunuen Rocío Huerta-Villalobos, T. Dedeu, Joaquim Mullol, Ruth Murray, A. Blua, Juan José Matta, Blanca Estela Del Río-Navarro, Daniel Laune, Daniela Rivero-Yeverino, María Dolores Mogica-Martínez, Victoria Cardona, José Miguel Fuentes-Pérez, Alejandra Macías-Weinmann, Isam Alobid, Anna Bedbrook, Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Vall d'Hebron University Hospital [Barcelona], IMIM-Hospital del Mar, Generalitat de Catalunya, Allergy Division, Fundacion Jimenez Diaz [Madrid] (FJD), LIBRA Foundation and CMP SA Buenos Aires, Fundación Cidea Allergy and Respiratory Research Unit, MedScript Ltd, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and Salvy-Córdoba, Nathalie

Subjects
0301 basic medicine, Allergy, Mobile app, m-Health, Spanish speaking, MASK-air, Allergic conjunctivitis, Allergic rhinitis, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, media_common.cataloged_instance, European union, Android (operating system), [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Asthma, media_common, ARIA, business.industry, Mobile apps, Spanish version, medicine.disease, 3. Good health, 030104 developmental biology, 030228 respiratory system, Medical emergency, business, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
Abstract

Aunque existen guías clínicas de alta calidad sobre rinitis alérgica, numerosos pacientes reciben tratamiento deficiente, en parte debido al alto grado de automedicación. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS; en ella, los pacientes indican diariamente cuánto les molestan los síntomas a través de cinco pantallas con una escala visual análoga; recientemente se agregaron dos pantallas más (afectación del sueño). La aplicación también permite descargar los datos del “Diario de alergias” en la computadora del médico en el momento de la consulta a través de un código QR. En este artículo reseñamos el primer año de experiencia en España, México y Argentina, que utilizan la versión española. Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the "Allergy Diary" on the physician's computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used.

Published
2019
Full Text
View/download PDF

17. [MASK (Mobile Airways Sentinel Network). ARIA's comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma]

Author

Larenas-Linnemann, Désirée, Mullol, Joaquim, Ivancevich, Juan Carlos, Antó, Josep, Cardona, Victoria, Dedeu, Toni, Rodriguez-González, Mónica, Huerta, Yunuen, Neffen, Hugo, Fuentes-Pérez, José Miguel, Rodriguez-Zagal, Eréndira, Valero, Antonio, Zernotti, Mario, Bartra, Joan, Alobid, Isam, Castillo-Vizuete, José Antonio, Dordal, Teresa, Hijano, Rafael, Picado, César, Sastre, Joaquin, Blua, Ariel Eduardo, Jares, Edgardo, Lavrut, Alberto Jorge, Máspero, Jorge, Bedolla-Barajas, Martin, Burguete, Maria, Costa, Maria Del Carmen, Dominguez-Silva, Margarita, Espinoza-Contreras, Jesús Guillermo, Gálvez-Romero, José Luis, Garcia-Cobas, Cecilia Yvonne, Garcia-Cruz, Maria de la Luz Hortensia, Hernández-Velázquez, Luiana, Luna-Pech, Jorge, Matta, Juan José, Mogica-Martinez, Maria Dolores, Rivero-Yeverino, Daniela, Ruiz-Segura, Lucy Tania, Del Rio-Navarro, Blanca, Gómez, Javier, Macias-Weinmann, Alejandra, Murray, Ruth, Onorato, Gabrielle, Laune, Daniel, Bedbrook, Anna, Bousquet, Jean, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Vall d'Hebron University Hospital [Barcelona], IMIM-Hospital del Mar, Generalitat de Catalunya, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
lcsh:Immunologic diseases. Allergy, app móvil, m-salud, conjuntivitis alérgica, ARIA, [SDV]Life Sciences [q-bio], m-Health, Mobil App, Multimorbidity, Self Medication, MASK-AIR, Allergic conjunctivitis, Mobile Applications, Rhinitis, Allergic, Allergic rhinitis, Asthma, asma, mask-aria, Humans, lcsh:RC581-607, rinitis alérgica, Conjunctivitis, Allergic
Abstract

International audience; The vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union againstchronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient’s cell phone, it fi rst requests some information about the patient’s profi le, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work / school. After analyzing the data generated by fi lling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries.; La mayor\'ia de los pacientes con rinitis alérgica no recibe el manejo idóneo, sino que se automedica. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS. Al descargarla al celular del paciente, a este se le piden datos de su perfil, patolog\'ias alérgicas y medicación; posteriormente, mediante una escala visual analógica se le invita a determinar el grado de afectación en nariz, ojos y bronquios y su influencia sobre su productividad laboral/escolar. Con los datos del Diario de Alergia se observa que existe un nuevo patrón de presentación: rinitis alérgica + conjuntivitis alérgica + asma, con mayor afectación, as\'i como un alto nivel de automedicación: en general, el paciente toma medicación cuando presenta s\'intomas. La app se ha desplegado en 23 pa\'ises, incluyendo varios pa\'ises hispanohablantes.

Published
2019
Full Text
View/download PDF

18. MASK (Mobile Airways Sentinel Network). La solución integral de ARIA por app móvil para la multimorbilidad de rinitis alérgica y asma

Author

Mario E. Zernotti, Juan José Matta, Erendira Rodriguez-Zagal, Joaquín Sastre, Jorge Maspero, Antonio Valero, Désirée Larenas-Linnemann, Joaquim Mullol, Jorge A. Luna-Pech, Yunuen Huerta, Gabrielle L. Onorato, María Burguete, Cecilia Yvonne García-Cobas, Juan Carlos Ivancevich, Daniela Rivero-Yeverino, Jesús Guillermo Espinoza-Contreras, Daniel Laune, César Picado, María Dolores Mogica-Martínez, A. Blua, Blanca Estela Del Río-Navarro, Margarita Domínguez-Silva, María del Carmen Costa, Edgardo Jares, T. Dedeu, Mónica Rodríguez-González, Anna Bedbrook, José Luis Gálvez-Romero, Josep M. Antó, Victoria Cardona, Joan Bartra, Luiana Hernández-Velázquez, María de la Luz Hortensia García-Cruz, Jean Bousquet, Alberto Jorge Lavrut, Isam Alobid, Javier Herrán Gómez, José Antonio Castillo-Vizuete, Martín Bedolla-Barajas, Hugo Neffen, José Miguel Fuentes-Pérez, Alejandra Macías-Weinmann, Rafael Hijano, Ruth Murray, Teresa Dordal, and Lucy Tania Ruiz-Segura

Subjects
Allergy, Rinitis alérgica, Visual analogue scale, m-Health, Mobil App, Allergic conjunctivitis, Allergic rhinitis, MASK-ARIA, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, media_common.cataloged_instance, 030212 general & internal medicine, Healthy aging, European union, Nose, Asma, Asthma, media_common, ARIA, business.industry, m-Salud, Mobile apps, MASK-AIR, medicine.disease, 3. Good health, medicine.anatomical_structure, 030228 respiratory system, App móvil, Medical emergency, Conjuntivitis alérgica, business
Abstract

La mayoría de los pacientes con rinitis alérgica no recibe el manejo idóneo, sino que se automedica. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS. Al descargarla al celular del paciente, a este se le piden datos de su perfil, patologías alérgicas y medicación; posteriormente, mediante una escala visual analógica se le invita a determinar el grado de afectación en nariz, ojos y bronquios y su influencia sobre su productividad laboral/escolar. Con los datos del Diario de Alergia se observa que existe un nuevo patrón de presentación: rinitis alérgica + conjuntivitis alérgica + asma, con mayor afectación, así como un alto nivel de automedicación: en general, el paciente toma medicación cuando presenta síntomas. La app se ha desplegado en 23 países, incluyendo varios países hispanohablantes. The vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union against chronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient’s cell phone, it first requests some information about the patient’s profile, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work / school. After analyzing the data generated by filling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results